Showing results (351-360 of 425) with videos related to
Sort By:
Pageof 43
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.Journal of Surgical Oncology|December 1, 2007
Electrical impedance scanning as a new breast cancer risk stratification tool for young womenAlexander Stojadinovic, Aviram Nissan, Craig D Shriver, et al.European Journal of Radiology|February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancerJorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.Lancet (London, England)|September 23, 2020
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialElizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, et al.Breast Cancer Research and Treatment|July 11, 2022
Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imagingMelissa B Aldrich, John C Rasmussen, Sarah M DeSnyder, et al.Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.JCO Precision Oncology|March 14, 2024
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer SubtypesReva K Basho, Li Zhao, Jason B White, et al.NPJ Breast Cancer|February 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)Sarah L Sammons, Thomas M Kuntz, Molly DiLullo, et al.JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.International Journal of Oncology|October 2, 2012
MUC1 glycopeptide epitopes predicted by computational glycomicsWei Song, Elizabeth S Delyria, Jieqing Chen, et al.Pageof 43